Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor indicated for hypertension, heart failure and acute myocardial infarction. We supply it to US manufacturers of tablets, oral solution and fixed-dose combinations.
Data from PubChem (CID 5362118) and FDA’s substance registry
CAS number
83915-83-7
Molecular formula
C21H35N3O7
Molecular weight
441.5g/mol
FDA UNII
IUPAC name
(2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;dihydrate
InChIKey
CZRQXSDBMCMPNJ-ZUIPZQNBSA-N
- Appearance
- White to off-white crystalline powder.
- Solubility
- Soluble in water, sparingly soluble in methanol and practically insoluble in ethanol.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Supplied as the dihydrate. The water content range and the limit for the diketopiperazine degradant are the figures to compare between sources.
On the US market
- Reference product
- ZestrilNDA 019777
- Approved ANDAs
- 14 with a marketed product
- Approved forms and strengths
- Tablet 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg
- Oral solution 1 mg/mL
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com